HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Vitreous Detachment (Posterior Vitreous Detachment)

Subscribe to New Research on Vitreous Detachment

Detachment of the corpus vitreum (VITREOUS BODY) from its normal attachments, especially the retina, due to shrinkage from degenerative or inflammatory conditions, trauma, myopia, or senility.

Also Known As:

Posterior Vitreous Detachment; Detachment, Posterior Vitreous; Detachment, Vitreous; Detachments, Posterior Vitreous; Detachments, Vitreous; Posterior Vitreous Detachments; Vitreous Detachment, Posterior; Vitreous Detachments; Vitreous Detachments, Posterior

Networked: 419 relevant articles (28 outcomes, 21 trials/studies)

Relationship Network

Disease Context: Research Results

Eye Diseases: 2132
- Vitreous Detachment: 419
  - type 2 Stickler syndrome: 3

Related Diseases

1.	Macular Edema
2.	Hemorrhage
3.	Retinal Perforations
4.	Vitreous Hemorrhage
5.	Macular Degeneration (Age-Related Maculopathy)

Experts

1.	de Smet, Marc D: 7 articles (02/2014 - 02/2009)
2.	Gandorfer, Arnd: 7 articles (11/2013 - 02/2004)
3.	Hirata, Akira: 6 articles (04/2013 - 04/2003)
4.	Kampik, Anselm: 6 articles (01/2013 - 02/2004)
5.	Trese, Michael T: 5 articles (01/2016 - 10/2007)
6.	Inoue, Makoto: 5 articles (10/2015 - 02/2007)
7.	Sebag, J: 5 articles (04/2015 - 08/2004)
8.	Hirakata, Akito: 4 articles (10/2015 - 08/2005)
9.	Duker, Jay S: 4 articles (09/2015 - 01/2012)
10.	Arevalo, J Fernando: 4 articles (01/2015 - 07/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vitreous Detachment:

1.	Fibrinolysin FDA Link 10/01/2004 - "To evaluate in a prospective study the efficacy of intrasurgical autologous plasmin enzyme (APE) in producing posterior vitreous detachment. " 01/01/2016 - "Plasmin can successfully cause vitreous liquefaction and induce a posterior vitreous detachment. " 01/01/2012 - "Plasmin plus SF(6) injection resulted in complete posterior vitreous detachment (PVD), whereas plasmin or SF(6) injection alone resulted in only partial PVD. " 03/01/2009 - "Intravitreal plasmin creates a posterior vitreous detachment, but may also liquefy the vitreous. " 06/01/2008 - "The use of plasmin for pharmacologic vitreolysis and the creation of a posterior vitreous detachment offers several potential advantages over surgery. "
2.	Retinaldehyde (Retinal)IBA 04/01/2007 - "The results of these studies have implications for the dosing, route of administration, duration of action and methods of determining efficacy in future studies of pharmacologic vitreolysis to enhance vitreo-retinal surgery, as well as the design of clinical trials to induce prophylactic posterior vitreous detachment." 05/01/2005 - "The purpose of this study was to evaluate the vitreoretinal border in the (pre-)equatorial area in nonpathologic human donor eyes, because the majority of retinal defects induced by posterior vitreous detachment (PVD) are located there. " 02/01/2015 - "Age was significantly associated with postmortem retinal fold formation (Mann-Whitney U test, P = 0.013), which led us to examine the effect of posterior vitreous detachment (PVD) on retinal folds. " 08/01/2014 - "Mean central retinal thickness changes were -113 μm (posterior vitreous detachment), -89 μm (release of vitreomacular adhesion), and -122 μm (vitreomacular adhesion) in monotherapy (P=.725) and -121 μm (posterior vitreous detachment), -113 μm (release of vitreomacular adhesion), and -113 μm (vitreomacular adhesion) in combination therapy (P=.924). " 11/01/2013 - "Focal vitreomacular adhesion is a nonpathologic anatomical designation associated with perifoveal posterior vitreous detachment but normal retinal morphology on OCT. "
3.	microplasminIBA 02/01/2011 - "Intravitreal recombinant microplasmin (MP) has been shown to successfully induce a posterior vitreous detachment (PVD) and vitreous liquefaction in animals. " 01/01/2011 - "Safety of the anterior vitreous detachment induced by microplasmin, or pharmacologic vitreolysis to separate the posterior capsule from the anterior hyaloid." 10/01/2010 - "Characterization of a stabilized form of microplasmin for the induction of posterior vitreous detachment." 09/01/2005 - "To investigate the safety of intravitreal microplasmin in rabbits and to confirm previous findings of posterior vitreous detachment (PVD). " 02/01/2004 - "Posterior vitreous detachment induced by microplasmin."
4.	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 02/01/2014 - "Hyaluronidase-treated eyes showed a similar clearance rate as group 3. In addition, group 3 showed a complete posterior vitreous detachment, which did not develop in hyaluronidase-treated eyes. " 01/01/2000 - "To investigate whether intravitreal injection of hyaluronidase can induce posterior vitreous detachment (PVD) in the rabbit. " 01/01/2000 - "Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit." 01/01/1998 - "Intravitreal injection of hyaluronidase in doses of 10 IU or higher induces posterior vitreous detachment in rabbits over a period of 5 weeks. " 01/01/1998 - "To investigate the efficacy and safety of intravitreal injection of hyaluronidase in producing liquefaction resulting in a posterior vitreous detachment. "
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/01/2014 - "The aim of this study was to determine the effect of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor injection. " 08/01/2015 - "Posterior vitreous detachment induced by anti-VEGF injections. " 04/01/2015 - "Secondary end points reported included VMA release over time, total posterior vitreous detachment (PVD), change in visual acuity from baseline, and number of anti-vascular endothelial growth factor (VEGF) injections. " 01/01/2014 - "Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration." 08/01/2015 - "To evaluate the incidence of posterior vitreous detachment (PVD) induced by intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents in cases of neovascular age-related macular degeneration (AMD). "
6.	bevacizumab FDA Link 05/01/2014 - "Our study suggests that posterior vitreous detachment may play a role in the efficacy of intravitreal bevacizumab during the treatment of neovascular age-related macular degeneration." 10/01/2011 - "To compare changes in posterior vitreous detachment (PVD) following intravitreal injection of bevacizumab and triamcinolone in diffuse diabetic macular edema in middle-aged type 2 diabetes patients and to correlate this change with change in central macular thickness (CMT). " 02/01/2011 - "Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes."
7.	Sulfur HexafluorideIBA 04/01/2004 - "The safety and efficacy of these agents and sulfur hexafluoride in inducing complete posterior vitreous detachment (total separation of the vitreous apart from vitreous base) were also evaluated. " 11/01/2000 - "Vitreous surgery was performed in a standard three-port fashion, with surgically induced posterior vitreous detachment, fluid-air exchange, and sulfur hexafluoride gas injection. " 04/01/2008 - "The preoperative best-corrected visual acuity (BCVA) was 20/100 and 20/40 in patient 1, 20/30 in patient 2, and 20/100 and 20/200 in patient 3. The vitreous surgery consisted of core vitrectomy, surgically induced posterior vitreous detachment (PVD), removal of the internal limiting membrane (except for the right eye of patient 1), and 30% sulfur hexafluoride gas tamponade. " 12/01/2000 - "Induced posterior vitreous detachment by intravitreal sulfur hexafluoride (SF6) injection in patients with nonproliferative diabetic retinopathy." 01/01/1999 - "Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous."
8.	Tissue Plasminogen Activator (Alteplase)FDA Link 01/01/2014 - "The induction of posterior vitreous detachment by using intravitreally administered recombinant tissue plasminogen activator (enzymatic vitreolysis) should be explored in further investigations." 01/01/2000 - "Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy." 11/01/2011 - "Intravitreal tissue plasminogen activator to treat refractory diabetic macular edema by induction of posterior vitreous detachment." 10/01/2007 - "To evaluate the effects of posterior vitreous detachment (PVD) in macular edema associated with central retinal vein occlusion (CRVO) treated with intravitreal tissue plasminogen activator (tPA). " 10/01/2007 - "Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion."
9.	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/01/2000 - "The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment." 01/01/2000 - "Posterior vitreous detachment can be produced in the rabbit eye using a combination of plasminogen and urokinase." 01/01/2000 - "To investigate the toxicity of intravitreal plasminogen, urokinase, and their combination, and to evaluate their efficacy in the production of posterior vitreous detachment (PVD) in the rabbit eye. " 11/01/2003 - "Vitreous detachment is considered to be induced safely and consistently by injection of plasmin prepared using a protein denaturation suppressor and activated with urokinase. " 02/01/2005 - "The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment."
10.	PlasminogenIBA 01/01/2000 - "The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment." 01/01/2013 - "Due to significantly increased intravitreal plasminogen in patients with recent onset of CRVO, intravitreally administered tissue plasminogen activator might be an option to induce posterior vitreous detachment (enzymatic vitreolysis) in CRVO patients." 01/01/2000 - "Posterior vitreous detachment can be produced in the rabbit eye using a combination of plasminogen and urokinase." 01/01/2000 - "To investigate the toxicity of intravitreal plasminogen, urokinase, and their combination, and to evaluate their efficacy in the production of posterior vitreous detachment (PVD) in the rabbit eye. " 02/01/2005 - "The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment."

Therapies and Procedures

1.	Vitrectomy 01/01/2012 - "Pars plana vitrectomy for optic disc pit-associated maculopathy was beneficial for improving visual acuity in two eyes without preoperative posterior vitreous detachment but not in two eyes with preoperative posterior vitreous detachment. " 01/01/2012 - "The purpose of this study was to evaluate the efficacy of pars plana vitrectomy for the treatment of optic disc pit-associated maculopathy with or without preoperative posterior vitreous detachment. " 09/01/2011 - "As spontaneous resolution may occur in some eyes with VMT following traumatic acute incomplete vitreous detachment, a period of observation may be considered prior to vitrectomy. " 01/01/2002 - "Pars plana vitrectomy, while offering superior results, should be reserved for patients who remain markedly symptomatic following vitreolysis, until future studies further clarify its role in the treatment of patients with floaters and posterior vitreous detachment." 04/01/1986 - "To study the effect of gravity on the location of RPE cell attachment, 3H-thymidine-labelled RPE cells were injected into 12 enucleated pig eyes after vitrectomy performed to create a posterior vitreous detachment. "
2.	Traction 07/01/2013 - "In one patient, rapid spontaneous resolution of the vitreomacular traction with a complete posterior vitreous detachment (PVD) and a normal foveal contour was achieved within 15 days. " 01/01/2010 - "To report a case of progressive vitreomacular traction, definitive optical coherence tomography evidence of established vitreomacular traction, and subsequent spontaneous resolution with posterior vitreous detachment occurrence. " 09/01/2015 - "She had a history of vitreomacular traction (VMT) that had resolved spontaneously with a complete posterior vitreous detachment. " 01/01/2015 - "At the macula, anomalous posterior vitreous detachment (PVD) results in either full-thickness vitreous cortex adhesion with vitreomacular traction syndrome, or partial-thickness adhesion due to vitreoschisis, a split in the posterior vitreous cortex. " 04/01/2014 - "Vitreo-macular traction followed by posterior vitreous detachment probably would have contributed to such a morphological event. "
3.	Laser Therapy (Surgery, Laser) 01/01/2011 - "This study investigates the efficacy of an intravitreal gas injection in inducing a posterior vitreous detachment (PVD) in patients with clinically significant diabetic macular edema refractory to laser therapy. " 06/01/2010 - "Seven eyes developed posterior vitreous detachment postoperatively, and 4 of these required prophylactic laser therapy for lattice degeneration and retinal breaks. " 01/01/2015 - "The central posterior vitrectomy combined with posterior vitreous detachment, laser therapy, andd expansile gas tamponade offers good outcomes in patients with retinal complications of optic disc pit. " 01/01/2015 - "9 patients (eyes) underwent central posterior vitrectomy in conjunction with posterior vitreous detachment, retinal laser therapy to the optic disc pit area and endotamponade with expansile gas. "
4.	Lasers (Laser) 04/01/2013 - "[Comparison of posterior vitreous detachment after femtosecond laser and microkeratome-assisted lase in situ keratomileusis]." 04/01/2010 - "To determine the ability to detect normal vitreous structure, evolving posterior vitreous detachment (PVD), and related vitreoretinal changes with combined spectral-domain optical coherence tomography (SD-OCT) and scanning laser ophthalmoscopy (SLO). " 04/01/2013 - "To compare the incidence of posterior vitreous detachment (PVD) early after femtosecond laser and microkeratome-assisted LASIK and their changes after follow-up observation. " 01/01/1990 - "Posterior vitreous detachment following panretinal laser photocoagulation." 01/01/2003 - "Laser treatment applied in accordance to general standards cased resolution of macular edema in all cases with posterior vitreous detachment. "
5.	Intravitreal Injections 01/01/2016 - "The ability to induce vitreous liquefaction and a complete posterior vitreous detachment (PVD) with a single intravitreal injection has potential implications for the management of multiple vitreoretinopathies. " 06/01/2015 - "One to 3 monthly intravitreal injections of 0.2ml of APE were applied, interrupting if posterior vitreous detachment was attained. " 07/01/2013 - "Intravitreal injection of commonly-used drugs seems to induce posterior vitreous detachment, which may thus influence the outcome of the underlying disease." 07/01/2013 - "To evaluate the incidence of posterior vitreous detachment (PVD) induced by intravitreal injection of different intravitreal drugs. " 06/01/2010 - "Consecutive intravitreal injections may alter the vitreous gel, thus inducing a posterior vitreous detachment or VMA. "